image
Healthcare - Medical - Diagnostics & Research - NASDAQ - IE
$ 0.55
4.89 %
$ 313 K
Market Cap
-0.25
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TRIB stock under the worst case scenario is HIDDEN Compared to the current market price of 0.55 USD, Trinity Biotech plc is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TRIB stock under the base case scenario is HIDDEN Compared to the current market price of 0.55 USD, Trinity Biotech plc is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TRIB stock under the best case scenario is HIDDEN Compared to the current market price of 0.55 USD, Trinity Biotech plc is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TRIB

image
$2.2$2.2$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0$0.8$0.8$0.6$0.6$0.4$0.4Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
56.8 M REVENUE
-24.00%
-27 M OPERATING INCOME
-147.82%
-24 M NET INCOME
41.43%
-11.6 M OPERATING CASH FLOW
-1154.83%
24.8 M INVESTING CASH FLOW
514.19%
-16 M FINANCING CASH FLOW
-30.19%
15.2 M REVENUE
-4.36%
-2.56 M OPERATING INCOME
36.87%
-4.76 M NET INCOME
29.57%
-3.62 M OPERATING CASH FLOW
-229.16%
-3.1 M INVESTING CASH FLOW
2.05%
4.24 M FINANCING CASH FLOW
-28.02%
Balance Sheet Trinity Biotech plc
image
Current Assets 39 M
Cash & Short-Term Investments 3.69 M
Receivables 13.4 M
Other Current Assets 22 M
Non-Current Assets 20.4 M
Long-Term Investments 214 K
PP&E 1.89 M
Other Non-Current Assets 18.3 M
6.21 %22.51 %36.96 %3.18 %30.77 %Total Assets$59.4m
Current Liabilities 15 M
Accounts Payable 3.88 M
Short-Term Debt 1.9 M
Other Current Liabilities 9.25 M
Non-Current Liabilities 68.3 M
Long-Term Debt 65.5 M
Other Non-Current Liabilities 2.83 M
4.66 %11.09 %78.58 %3.39 %Total Liabilities$83.4m
EFFICIENCY
Earnings Waterfall Trinity Biotech plc
image
Revenue 56.8 M
Cost Of Revenue 37.4 M
Gross Profit 19.4 M
Operating Expenses 46.5 M
Operating Income -27 M
Other Expenses -3.03 M
Net Income -24 M
60m60m50m50m40m40m30m30m20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)57m(37m)19m(46m)(27m)3m(24m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
34.22% GROSS MARGIN
34.22%
-47.59% OPERATING MARGIN
-47.59%
-42.26% NET MARGIN
-42.26%
100.29% ROE
100.29%
-40.41% ROA
-40.41%
-58.31% ROIC
-58.31%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Trinity Biotech plc
image
15m15m10m10m5m5m00(5m)(5m)(10m)(10m)(15m)(15m)20152015201620162017201720182018201920192020202020212021202220222023202320242024
Net Income -24 M
Depreciation & Amortization 1.78 M
Capital Expenditures -803 K
Stock-Based Compensation 2.07 M
Change in Working Capital -2.69 M
Others 11.4 M
Free Cash Flow -14.3 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Trinity Biotech plc
image
TRIB has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
1.1 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
1.21.21.01.00.80.80.60.60.40.40.20.20.00.01.11.1020152015
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Trinity Biotech plc
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares and Nasdaq Minimum Bid Price Requirement DUBLIN, March 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice today from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), requiring that listed securities maintain a minimum bid price of US $1.00 per share, based on the closing bid price of the Company's American depositary shares (“ADSs”) for the last 30 consecutive business days. The Company also received notice today that the Company no longer meets the requirement in Nasdaq Listing Rule 5450(b) that listed securities maintain a minimum market value of publicly held shares (“MVPHS”) of US $15,000,000, based on Nasdaq's review of the Company's MVPHS for the last 30 consecutive business days. globenewswire.com - 1 month ago
Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process DUBLIN and PORTLAND, Ore., March 13, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the next stage in realizing its comprehensive transformation plan and development of its continuous glucose monitoring (“CGM”) technology with the appointment of Barclays Capital Inc. (“Barclays”) as its exclusive financial advisor to support its ongoing strategic realignment, reflecting the Company's increased focus on its CGM technology as part of its broader transformation plan. globenewswire.com - 1 month ago
Trinity Biotech Announces Additional Funding To Support Transformation Plan & Continued Development of the Company's Continuous Glucose Monitoring Technology DUBLIN, Ireland, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has obtained an additional $4m in debt financing from its primary lender, Perceptive Advisors. globenewswire.com - 2 months ago
Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial Trinity Biotech's patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029 Trinity Biotech's patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029 globenewswire.com - 2 months ago
Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology Trinity Biotech's patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029 Trinity Biotech's patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029 globenewswire.com - 3 months ago
Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan DUBLIN, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has entered into amended agreements with its primary lender, Perceptive Advisors. These strategic amendments provide additional liquidity, further enhancing the Company's near-term financial position as it advances its Comprehensive Transformation Plan and continues development of its innovative continuous glucose monitoring (CGM) technology. globenewswire.com - 4 months ago
Trinity Biotech Receives Early Approval from the World Health Organization to Begin Offshore Manufacturing of TrinScreen HIV & Uni-Gold HIV DUBLIN, Ireland, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced an important update on its Comprehensive Transformation Plan, which includes the transfer of manufacturing of both TrinScreen HIV and Uni-Gold HIV to a lower-cost offshore manufacturing partner. Trinity Biotech has received earlier than expected approval from the World Health Organization (WHO) to permit the later-stage manufacturing process of TrinScreen HIV and Uni-Gold HIV at its outsourced provider. This approval was a key prerequisite in the manufacturing transfer the Company has been working towards as part of its Comprehensive Transformation Plan. globenewswire.com - 4 months ago
Trinity Biotech Plc (TRIB) Q3 2024 Earnings Call Transcript Trinity Biotech Plc (NASDAQ:TRIB ) Q3 2024 Earnings Conference Call November 15, 2024 10:00 AM ET Company Participants Eric Ribner - Investor Relations John Gillard – President, Chief Executive Officer Louise Tallon - Chief Financial Officer Conference Call Participants James Sidoti - Sidoti & Company Paul Nouri – Noble Equity Funds Operator Greetings. Welcome to the Trinity Biotech Third Quarter 2024 Earnings Conference Call. seekingalpha.com - 5 months ago
Trinity Biotech Announces Q3 2024 Financial Results Q3 2024 total revenue of $15.2 million grew +3% Y/Y based on strong demand and output in the TrinScreen HIV business Point-of-Care product revenue of $4.3 million grew 60% Y/Y Reiterates guidance to achieve approximately $20 million of annualized run-rate EBITDASO1 on annualized run-rate revenues of approximately $75 million by Q2 2025 Reiterates guidance to achieve 2024 sales revenue for TrinScreen HIV of approximately $10 million DUBLIN, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the Company's results for the quarter ended September 30, 2024. Key Highlights and Developments Continued Revenue and Profitability Improvements Year-over-year revenue growth of 3% and continued disciplined execution on our profitability enhancing initiatives contributed to a decrease in the operating loss (before restructuring and impairment charges) to $2.2 million from $4.5m in Q3 2023, a 51% improvement. globenewswire.com - 5 months ago
Trinity Biotech to Announce Q3 2024 Financial Results Conference Call Scheduled for Friday, November 15, 2024 at 10:00 AM ET Conference Call Scheduled for Friday, November 15, 2024 at 10:00 AM ET globenewswire.com - 5 months ago
Trinity Biotech Regains Compliance with Nasdaq Listing Requirements DUBLIN, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq Global Select: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that on November 6, 2024, it received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the minimum market value of publicly held shares (“MVPHS”) requirement under Nasdaq Listing Rule 5450(b)(2)(C) (the “MVPHS Requirement”). globenewswire.com - 5 months ago
Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture DUBLIN, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the acquisition of EpiCapture Limited, a company developing a non-invasive test for monitoring the risk of aggressive prostate cancer. This acquisition marks Trinity Biotech's strategic expansion into the oncology diagnostics market. globenewswire.com - 6 months ago
8. Profile Summary

Trinity Biotech plc TRIB

image
COUNTRY IE
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 313 K
Dividend Yield 0.00%
Description Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Contact IDA Business Park, Bray, A98 H5C8 https://www.trinitybiotech.com
IPO Date Oct. 21, 1992
Employees 380
Officers Mr. John Gillard President, Chief Executive Officer, Company Secretary & Director Ms. Jacqueline O'Neill Director of Operations Ms. Louise Tallon Chief Accounting Officer Dr. Gary Keating Ph.D. Chief Technology Officer Mr. Colm Molloy Group Director of Human Resources & Culture Mr. Adrian Donohue Chief Commercial Officer Ms. Susan O'Connor Interim Chief Financial Officer Ms. Eibhlin Kelly Chief Information Officer Mr. Ronan O'Caoimh A.C.A. Founder, Director & Executive Advisor Dr. James Walsh Ph.D. Executive Director of Business Development & Executive Director